Travere Therapeutics' FILSPARI Receives FDA Approval for FSGS Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Travere Therapeutics Inc. (TVTX) is experiencing a significant price increase of 46.06% in pre-market trading, reaching a 52-week high.
The surge is primarily due to the FDA's approval of Travere's FILSPARI as the first medication for treating focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, which could benefit over 100,000 patients in the U.S. The approval is supported by clinical trial results showing a 48% reduction in proteinuria over 108 weeks, significantly outperforming the control drug. This milestone not only enhances Travere's market position but also opens new avenues for growth in the rare kidney disease sector.
The approval of FILSPARI is expected to drive substantial commercial growth for Travere, with projections indicating a significant increase in market share and product sales. The company has also launched a patient support program to assist patients in navigating their treatment options, further solidifying its commitment to improving patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to fall
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 44.740
Low
31.00
Averages
42.89
High
49.00
Current: 44.740
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On May 10, 2026, Travere Therapeutics granted inducement equity awards totaling 48,800 shares to four new employees, comprising 18,000 inducement stock options and 30,800 inducement restricted stock units (RSUs), aimed at attracting new talent to the company.
- Stock Option Details: The stock options have an exercise price of $43.51 per share, based on the closing price on the next trading day after the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests after one year and the remaining 75% vests monthly over the following 36 months, ensuring employee retention.
- RSU Vesting Structure: The inducement RSUs also vest over four years, with 25% vesting each year, which not only incentivizes long-term employee commitment but also enhances the company's attractiveness to new hires, complying with Nasdaq Listing Rule requirements.
- Company Mission and Vision: Travere Therapeutics is dedicated to providing urgently needed treatment options for patients with rare diseases, with a global team collaborating with the rare disease community to develop and deliver life-changing therapies, highlighting the strategic significance of the company in the biopharmaceutical sector.
See More
Roy D. Baynes Sells Shares in Travere Therapeutics Under 10b5-1 Plan
- Transaction Overview: Roy D. Baynes, Director at Travere Therapeutics, reported the exercise and immediate sale of 4,500 common shares for approximately $210,000, indicating a need for liquidity amidst his ongoing stock management strategy.
- Ownership Change Analysis: Following this transaction, Baynes's direct holdings decreased by 4,500 shares, representing a 10.71% reduction, leaving him with 37,500 shares, which suggests a strategic shift in his ownership stake in the company.
- Transaction Structure Insight: The sale involved exercising fully vested options at a strike price of $18.27 and selling at $46.65, netting around $127,700, which highlights his strategy of capitalizing on high market prices.
- Investor Signal: Although this transaction was executed under a 10b5-1 plan adopted in November 2025, it should not be interpreted as a negative signal regarding Travere's recent performance, as Baynes still retains shares valued at approximately $1.6 million.
See More
Director Roy D. Baynes Sells Shares of Travere Therapeutics
- Stock Option Exercise: On May 5, 2026, Roy D. Baynes exercised 4,500 stock options and sold them at a weighted average price of approximately $46.65 per share, totaling around $210,000, which reduced his direct holdings from 42,000 to 37,500 shares, indicating a strategic adjustment in his ownership stake.
- Transparent Trading Plan: This transaction was executed under a 10b5-1 plan adopted by Baynes in November 2025, indicating that the sale was unrelated to any developments at Travere in May 2026, thus preventing misinterpretation of the sale as a directional signal and ensuring compliance and transparency in the process.
- Market Performance Analysis: At the time of the transaction, Travere's stock traded within a 52-week range of $13.88 to $48.61, with the sale occurring near the top of this range, reflecting Baynes's strategy to reduce his position at a high point, even as he retains approximately $1.6 million worth of shares.
- Investor Caution: Despite Baynes's sale potentially raising eyebrows, the Motley Fool analyst team noted that Travere Therapeutics was not included in their list of the 10 best stocks to buy, suggesting that investors should exercise caution when considering purchases in the current market environment.
See More
Travere Therapeutics Prices $475M Convertible Notes Offering
- Increased Offering Size: Travere Therapeutics announced the pricing of its $475 million convertible notes offering, which was raised from the previously announced $400 million, indicating strong market demand for its financing needs, with the transaction expected to close on May 11.
- Underwriter's Option: The company granted underwriters a 30-day option to purchase up to an additional $50 million of the notes to cover over-allotments, a strategy that enhances the flexibility of its capital structure.
- Stock Price Reaction: Travere's shares fell 1.9% in after-hours trading, reflecting cautious market sentiment regarding the financing, which may impact investor confidence in the company's future growth potential.
- Financial Performance Overview: Although the company reported a non-GAAP EPS of $0.05, beating expectations, its revenue of $124.5 million fell short by $12.27 million, indicating challenges in revenue growth for the company.
See More
Travere Therapeutics Prices $475 Million Convertible Notes Offering
- Increased Offering Size: Travere Therapeutics announced an increase in its convertible senior notes offering from $400 million to $475 million, reflecting strong market demand, with the transaction expected to close on May 11, 2026, thereby enhancing the company's capital structure.
- Clear Use of Proceeds: The offering is expected to generate approximately $460 million in net proceeds, with about $350.9 million allocated for repurchasing outstanding 2.25% convertible notes due 2029, aimed at optimizing debt structure and reducing interest burden.
- Flexible Conversion Terms: The initial conversion rate is set at 15.4078 shares per $1,000 principal amount, translating to an approximate conversion price of $64.90 per share, providing investors with flexible conversion options that may attract more participation.
- Market Reaction Anticipated: The concurrent repurchase transactions may lead holders to unwind hedging positions, potentially impacting Travere's common stock price and increasing the effective conversion price of the notes, thereby influencing market dynamics.
See More
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On May 10, 2026, Travere Therapeutics granted inducement equity awards totaling 48,800 shares to four new employees, comprising 18,000 inducement stock options and 30,800 inducement restricted stock units (RSUs), aimed at attracting new talent to the company.
- Stock Option Details: The stock options have an exercise price of $43.51 per share, based on the closing price on the next trading day after the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests after one year and the remaining 75% vests monthly over the following 36 months, ensuring employee retention.
- RSU Vesting Structure: The inducement RSUs also vest over four years, with 25% vesting each year, which not only incentivizes long-term employee commitment but also enhances the company's attractiveness to new hires, complying with Nasdaq Listing Rule requirements.
- Company Mission and Vision: Travere Therapeutics is dedicated to providing urgently needed treatment options for patients with rare diseases, with a global team collaborating with the rare disease community to develop and deliver life-changing therapies, highlighting the strategic significance of the company in the biopharmaceutical sector.
See More
Roy D. Baynes Sells Shares in Travere Therapeutics Under 10b5-1 Plan
- Transaction Overview: Roy D. Baynes, Director at Travere Therapeutics, reported the exercise and immediate sale of 4,500 common shares for approximately $210,000, indicating a need for liquidity amidst his ongoing stock management strategy.
- Ownership Change Analysis: Following this transaction, Baynes's direct holdings decreased by 4,500 shares, representing a 10.71% reduction, leaving him with 37,500 shares, which suggests a strategic shift in his ownership stake in the company.
- Transaction Structure Insight: The sale involved exercising fully vested options at a strike price of $18.27 and selling at $46.65, netting around $127,700, which highlights his strategy of capitalizing on high market prices.
- Investor Signal: Although this transaction was executed under a 10b5-1 plan adopted in November 2025, it should not be interpreted as a negative signal regarding Travere's recent performance, as Baynes still retains shares valued at approximately $1.6 million.
See More
Director Roy D. Baynes Sells Shares of Travere Therapeutics
- Stock Option Exercise: On May 5, 2026, Roy D. Baynes exercised 4,500 stock options and sold them at a weighted average price of approximately $46.65 per share, totaling around $210,000, which reduced his direct holdings from 42,000 to 37,500 shares, indicating a strategic adjustment in his ownership stake.
- Transparent Trading Plan: This transaction was executed under a 10b5-1 plan adopted by Baynes in November 2025, indicating that the sale was unrelated to any developments at Travere in May 2026, thus preventing misinterpretation of the sale as a directional signal and ensuring compliance and transparency in the process.
- Market Performance Analysis: At the time of the transaction, Travere's stock traded within a 52-week range of $13.88 to $48.61, with the sale occurring near the top of this range, reflecting Baynes's strategy to reduce his position at a high point, even as he retains approximately $1.6 million worth of shares.
- Investor Caution: Despite Baynes's sale potentially raising eyebrows, the Motley Fool analyst team noted that Travere Therapeutics was not included in their list of the 10 best stocks to buy, suggesting that investors should exercise caution when considering purchases in the current market environment.
See More
Travere Therapeutics Prices $475M Convertible Notes Offering
- Increased Offering Size: Travere Therapeutics announced the pricing of its $475 million convertible notes offering, which was raised from the previously announced $400 million, indicating strong market demand for its financing needs, with the transaction expected to close on May 11.
- Underwriter's Option: The company granted underwriters a 30-day option to purchase up to an additional $50 million of the notes to cover over-allotments, a strategy that enhances the flexibility of its capital structure.
- Stock Price Reaction: Travere's shares fell 1.9% in after-hours trading, reflecting cautious market sentiment regarding the financing, which may impact investor confidence in the company's future growth potential.
- Financial Performance Overview: Although the company reported a non-GAAP EPS of $0.05, beating expectations, its revenue of $124.5 million fell short by $12.27 million, indicating challenges in revenue growth for the company.
See More
Travere Therapeutics Prices $475 Million Convertible Notes Offering
- Increased Offering Size: Travere Therapeutics announced an increase in its convertible senior notes offering from $400 million to $475 million, reflecting strong market demand, with the transaction expected to close on May 11, 2026, thereby enhancing the company's capital structure.
- Clear Use of Proceeds: The offering is expected to generate approximately $460 million in net proceeds, with about $350.9 million allocated for repurchasing outstanding 2.25% convertible notes due 2029, aimed at optimizing debt structure and reducing interest burden.
- Flexible Conversion Terms: The initial conversion rate is set at 15.4078 shares per $1,000 principal amount, translating to an approximate conversion price of $64.90 per share, providing investors with flexible conversion options that may attract more participation.
- Market Reaction Anticipated: The concurrent repurchase transactions may lead holders to unwind hedging positions, potentially impacting Travere's common stock price and increasing the effective conversion price of the notes, thereby influencing market dynamics.
See More
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
